Portal de investigación
Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country
Fecha de publicación:
Autores organización
Autores
- Cifuentes C.
- Lombana M.
- Vargas H.
- Laguado P.
- Ruiz-Patiño A.
- Navarro U.
- Vargas C.
- Ricaurte L.
- Arrieta O.
- Zatarain-Barron L.
- Zapata L.
- González G.
- Ortiz C.
- Bernal L.
- Restrepo J.G.
- Viola L.
- Grosso F.
- Zapata R.
- Mantilla W.
- Carranza H.
- Bustillo I.
- Llinas N.
- Duarte R.
- Rodríguez J.
- Archila P.
- Ávila J.
- Bermúdez M.
- Gámez T.
- Sotelo C.
- Otero J.
- Forero E.
- Lema M.
- Limpias C.
- Ordóñez-Reyes C.
- Mejía S.
- Rolfo C.
- Rosell R.
Grupos de investigación
Resumen
Purpose: Identifying actionable oncogenic mutations have changed the therapeutic landscape in different types of tumors. This study investigated the utility of comprehensive genomic profiling (CGP), a hybrid capture-based next-generation sequencing (NGS) assay, in clinical practice in a developing country. Methods: In this retrospective cohort study, CGP was performed on clinical samples from patients with different solid tumors recruited between December 2016 and November 2020, using hybrid capture-based genomic profiling, at the individual treating physicians’ request in the clinical care for therapy decisions. Kaplan–Meier survival curves were estimated to characterize the time-to-event variables. Results: Patients median age was 61 years (range: 14–87 years), and 64.7% were female. The most common histological diagnosis was lung primary tumors, with 90 patients corresponding to 52.9% of the samples (95% CI 45.4-60.4%). Actionable mutations with FDA-approved medications for specific alterations correspondent to tumoral histology were identified in 58 cases (46.4%), whereas other alterations were detected in 47 different samples (37.6%). The median overall survival was 15.5 months (95% CI 11.7 months-NR). Patients who were subjected to genomic evaluation at diagnosis reached a median overall survival of 18.3 months (95% CI 14.9 months-NR) compared to 14.1 months (95% CI 11.1 months-NR) in patients who obtained genomic evaluation after tumor progression and during standard treatment (P =.7). Conclusion: CGP of different types of tumors identifies clinically relevant genomic alterations that have benefited from targeted therapy and improve cancer care in a developing country to guide personalized treatment to beneficial outcomes of cancer patients. © The Author(s) 2023.
Datos de la publicación
- ISSN/ISSNe:
- 1073-2748, 1526-2359
- Tipo:
- Article
- Páginas:
- -
- Enlace a otro recurso:
- www.scopus.com
Cancer Control SAGE Publications Ltd
Citas Recibidas en Scopus: 3
Documentos
- No hay documentos
Filiaciones
Keywords
- Developing Countries; Female; Genomics; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Retrospective Studies; antineoplastic metal complex; atezolizumab; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; pembrolizumab; pemetrexed; adolescent; adult; aged; Article; cancer patient; cancer therapy; cohort analysis; comprehensive genomic profiling; controlled study; developing country; female; Food and Drug Administration; gene mutation; genetic profile; high throughput sequencing; histology; human; Kaplan Meier method; lung tumor; major clinical study; male; oncogenomics; overall survival; personalized medicine; primary tumor; retrospective study; solid tumor; tumor growth; developed country; genomics; high throughput sequencing; lung tumor; middle aged; mutation; pathology
Financiación
Proyectos asociados
Citar la publicación
Cifuentes C,Lombana M,Vargas H,Laguado P,Ruiz A,Rojas L,Navarro U,Vargas C,Ricaurte L,Arrieta O,Zatarain L,Zapata L,González G,Ortiz C,Bernal L,Restrepo JG,Viola L,Grosso F,Zapata R,Mantilla W,Carranza H,Bustillo I,Llinas N,Duarte R,Rodríguez J,Archila P,Ávila J,Bermúdez M,Gámez T,Sotelo C,Otero J,Forero E,Lema M,Limpias C,Ordóñez C,Mejía S,Rolfo C,Rosell R,Cardona AF. Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country. Cancer Control. 2023. 30. 10732748231175256. IF:2,500. (3).